These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 32935106)

  • 1. Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease.
    Pavlova A; Lynch DL; Daidone I; Zanetti-Polzi L; Smith MD; Chipot C; Kneller DW; Kovalevsky A; Coates L; Golosov AA; Dickson CJ; Velez-Vega C; Duca JS; Vermaas JV; Pang YT; Acharya A; Parks JM; Smith JC; Gumbart JC
    bioRxiv; 2020 Sep; ():. PubMed ID: 32935106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor binding influences the protonation states of histidines in SARS-CoV-2 main protease.
    Pavlova A; Lynch DL; Daidone I; Zanetti-Polzi L; Smith MD; Chipot C; Kneller DW; Kovalevsky A; Coates L; Golosov AA; Dickson CJ; Velez-Vega C; Duca JS; Vermaas JV; Pang YT; Acharya A; Parks JM; Smith JC; Gumbart JC
    Chem Sci; 2021 Jan; 12(4):1513-1527. PubMed ID: 35356437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Awoonor-Williams E; Abu-Saleh AAA
    Phys Chem Chem Phys; 2021 Mar; 23(11):6746-6757. PubMed ID: 33711090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights into SARS-CoV-2 main protease conformational plasticity.
    Dehury B; Mishra S; Pati S
    J Cell Biochem; 2023 Jun; 124(6):861-876. PubMed ID: 37099673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease.
    Ferreira JC; Fadl S; Villanueva AJ; Rabeh WM
    Front Chem; 2021; 9():692168. PubMed ID: 34249864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH profiles of 3-chymotrypsin-like protease (3CLpro) from SARS-CoV-2 elucidate its catalytic mechanism and a histidine residue critical for activity.
    Al Adem K; Ferreira JC; Fadl S; Rabeh WM
    J Biol Chem; 2023 Feb; 299(2):102790. PubMed ID: 36509143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography.
    Kneller DW; Phillips G; Weiss KL; Zhang Q; Coates L; Kovalevsky A
    J Med Chem; 2021 Apr; 64(8):4991-5000. PubMed ID: 33755450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the binding and covalent inhibition mechanism of PF-07321332 to SARS-CoV-2 M
    Ngo ST; Nguyen TH; Tung NT; Mai BK
    RSC Adv; 2022 Jan; 12(6):3729-3737. PubMed ID: 35425393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of proton-coupled conformational dynamics of SARS and MERS coronavirus papain-like proteases: Implication for designing broad-spectrum antiviral inhibitors.
    Henderson JA; Verma N; Harris RC; Liu R; Shen J
    J Chem Phys; 2020 Sep; 153(11):115101. PubMed ID: 32962355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL M
    Kneller DW; Phillips G; O'Neill HM; Tan K; Joachimiak A; Coates L; Kovalevsky A
    IUCrJ; 2020 Sep; 7(Pt 6):1028-35. PubMed ID: 33063790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
    Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
    Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for substrate binding-induced zwitterion formation in the catalytic Cys-His dyad of the SARS-CoV main protease.
    Paasche A; Zipper A; Schäfer S; Ziebuhr J; Schirmeister T; Engels B
    Biochemistry; 2014 Sep; 53(37):5930-46. PubMed ID: 25196915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cordifolioside: potent inhibitor against M
    Manne M; Goudar G; Varikasuvu SR; Khetagoudar MC; Kanipakam H; Natarajan P; Ummiti MD; Yenagi VA; Chinthakindi S; Dharani P; Thota DSS; Patil S; Patil V
    3 Biotech; 2021 Mar; 11(3):136. PubMed ID: 33643762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple protonation states in ligand-free SARS-CoV-2 main protease revealed by large-scale quantum molecular dynamics simulations.
    Ono J; Koshimizu U; Fukunishi Y; Nakai H
    Chem Phys Lett; 2022 May; 794():139489. PubMed ID: 35221345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of the prototypical α-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex.
    Liang J; Pitsillou E; Karagiannis C; Darmawan KK; Ng K; Hung A; Karagiannis TC
    Comput Biol Chem; 2020 May; 87():107292. PubMed ID: 32485652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study.
    Das S; Sarmah S; Lyndem S; Singha Roy A
    J Biomol Struct Dyn; 2021 Jun; 39(9):3347-3357. PubMed ID: 32362245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral agents against COVID-19: structure-based design of specific peptidomimetic inhibitors of SARS-CoV-2 main protease.
    Frecer V; Miertus S
    RSC Adv; 2020 Nov; 10(66):40244-40263. PubMed ID: 35520818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An insight into the interaction between α-ketoamide- based inhibitor and coronavirus main protease: A detailed in silico study.
    Banerjee S
    Biophys Chem; 2021 Feb; 269():106510. PubMed ID: 33285430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.